Congress trades and big insider sales, sent the day they're filed. Free.
Open in Telegram
Chief Medical Officer · ENANTA PHARMACEUTICALS INC · ENANTA PHARMACEUTICALS INC — Stock Option (right to buy)
Grant or award — administrative, little informational value
No reported dollar value · new position
Disclosed 1 business day after execution (deadline: 2)
First recorded trade by this actor in this security
No clustered activity in the dataset
No material company filing within 60 days after the trade
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
| Score | Actor | Security | Side | Value | Disclosed | Evidence |
|---|---|---|---|---|---|---|
| 9 | Rottinghaus Scott T.Chief Medical Officer | Tax withholding | F | $20K 1,467 sh | Aug 10, 2026 traded Aug 8, 2026 | |
| 9 | Russell LesleyDirector | Grant or award | A | — 20.0K sh | Mar 13, 2026 traded Mar 11, 2026 | |
| 9 | Carter Bruce L ADirector | Grant or award | A | — 20.0K sh | Mar 13, 2026 traded Mar 11, 2026 | |
| 9 | Hata Yujiro SDirector | Grant or award | A | — 20.0K sh | Mar 13, 2026 traded Mar 11, 2026 | |
| 9 | Peterson KristineDirector | Grant or award | A | — 20.0K sh | Mar 13, 2026 traded Mar 11, 2026 | |
| 9 | Vance TerryDirector | Grant or award | A | — 20.0K sh | Mar 13, 2026 traded Mar 11, 2026 | |
| 9 | Foletta Mark GDirector | Grant or award | A | — 20.0K sh | Mar 13, 2026 traded Mar 11, 2026 | |
| 21 | Kowalsky Matthew PaulChief Legal Officer | Tax withholding | F | $27K 1,902 sh | Feb 13, 2026 traded Feb 12, 2026 | |
| 5 | Luly Jay R.Director, President and CEO | Grant or award | A | — 4,800 sh | Feb 13, 2026 traded Feb 12, 2026 | |
| 5 | Or Yat SunChief Scientific Officer | Grant or award | A | — 1,650 sh | Feb 13, 2026 traded Feb 12, 2026 | |
| 9 | Kieffer Tara LynnChief Product Strategy Officer | Grant or award | A | — 4,987 sh | Feb 13, 2026 traded Feb 12, 2026 | |
| 9 | Kowalsky Matthew PaulChief Legal Officer | Grant or award | A | — 1,318 sh | Feb 13, 2026 traded Feb 12, 2026 | |
| 9 | Luu BrendanChief Business Officer | Tax withholding | F | $46K 3,257 sh | Feb 13, 2026 traded Feb 12, 2026 | |
| 21 | Kowalsky Matthew PaulChief Legal Officer | Grant or award | A | — 4,175 sh | Feb 13, 2026 traded Feb 12, 2026 | |
| 5 | Or Yat SunChief Scientific Officer | Grant or award | A | — 5,225 sh | Feb 13, 2026 traded Feb 12, 2026 | |
| 5 | Luu BrendanChief Business Officer | Grant or award | A | — 1,575 sh | Feb 13, 2026 traded Feb 12, 2026 | |
| 5 | Luly Jay R.Director, President and CEO | Grant or award | A | — 15.2K sh | Feb 13, 2026 traded Feb 12, 2026 | |
| 13 | Rottinghaus Scott T.Chief Medical Officer | Grant or award | A | — 5,225 sh | Feb 13, 2026 traded Feb 12, 2026 | |
| 9 | Rottinghaus Scott T.Chief Medical Officer | Grant or award | A | — 1,650 sh | Feb 13, 2026 traded Feb 12, 2026 | |
| 8 | Luly Jay R.Director, President and CEO | Tax withholding | F | $88K 6,155 sh | Feb 13, 2026 traded Feb 12, 2026 |
Read directly from the primary public document; every field below is as reported by the filer.
Rottinghaus Scott T. filed this Form 4 reporting a grant or award of ENTA on Nov 25, 2025. It became public on Nov 26, 2025. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
No field has changed since this record was first ingested.
No material filings recorded for this issuer.